Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Yatomi, T. Hisada, M. Nishioka, Y. Kamide, H. Tsurumaki, H. Aoki, K. Seki, R. Yoshino, A. Ono, Y. Koga, K. Dobashi, T. Ishizuka, M. Mori (Maebashi, Shibukawa, Fukui, Japan). 17(R)-resolvin D1 attenuates bleomycin-induced lung fibrosis in mice. Eur Respir J 2013; 42: Suppl. 57, 532

Member's Comments

No comment yet.

Related content which might interest you: Treprostinil administration attenuates bleomycin-induced lung fibrosis in mice Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 17(R)-resolvinD1 improves MMP-9/TIMP-1 imbalance leading to amelioration of pulmonary fibrosis in mice Source: International Congress 2016 – ILD pathogenesis Year: 2016 Effects of NecroX compounds on bleomycin-induced pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Novel biomarkers in bleomycin-induced pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 The role of expression of TLR 4 in bleomycin-induced pulmonary fibrosis in mice Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury Year: 2013 Selective endothelin-A receptor blockade attenuates bleomycin-induced pulmonary inflammation and fibrosis in mice Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 17(R)-resolvin D1 ameliorates bleomycin-induced pulmonary fibrosis in mice via decreasing MCP-1 mRNA Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Sulforaphane attenuates lung fibrosis in bleomycin-induced pulmonary fibrosis via inhibition of TGF-beta/Smad signaling Source: International Congress 2014 – ILDs 4 Year: 2014 Role of dendritic cells in pulmonary fibrosis in mice Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Nintedanib reduces bleomycin-induced lung inflammation and fibrosis in mice Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 New approach to the treatment of bleomycin-induced lung fibrosis using pulmonary surfactant as pirfenidone carrier into the lung Source: International Congress 2015 – Inflammation and remodelling in lung disease Year: 2015 Effect of intratracheal administration of adipose-derived stromal cells on bleomycin-induced lung injury in a rat model Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 Aquoaporin-1 expression in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Increased levels of oxidative stress markers in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 The immunomodulatory effect of protein S in pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Serum surfactant protein D may predict the effect of pirfenidone in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Role of midkine in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Pirfenidone attenuates myofibroblast differentiation during insufficient mitophagy Source: International Congress 2016 – IPF pathogenesis Year: 2016 HSP47siRNA targeting to myofibroblasts attenuates bleomycin-induced pulmonary fibrosis Source: Annual Congress 2012 - Interstitial lung disease: from bench to bedside Year: 2012